Insights - Shares of Exact Sciences (EXAS) ripped higher on Friday with news that reimbursement for Cologuard should come in at the high end of analyst and investor … Continue Reading
Read nowResearch - Our view is that QLT Inc's (QLTI) board will find a way to wind down the business in a favorable manner.
Read nowInsights - Endo Health (ENDP) and Auxilium Pharmaceuticals (AUXL) finally came to terms in ongoing buyout negotiations, with ENDP handing over $2.6 billion ($33.25 per share) in … Continue Reading
Read nowResearch - Late-breaking abstracts from AASLD’s upcoming The Liver Meeting were published on Tuesday morning at 10:00 AM, and a number of companies with development-stage therapeutics in the space felt the impact. … Continue Reading
Read nowResearch - Alcobra (ADHD) reported results on Monday morning from a phase 3 trial of metadoxine sustained-release in adult ADHD patients. While the company spins the results as positive based … Continue Reading
PremiumInsights - Sunesis Pharmaceuticals (SNSS) announced Monday much-anticipated results from the pivotal Phase 3 VALOR trial, a randomized, double-blind, placebo-controlled trial of vosaroxin (trademark Qinprezo) and cytarabine in … Continue Reading
Read nowResearch - Alcobra Pharma (ADHD) announced on September 19 that all scheduled follow-up visits had been complete in the company’s phase 3 clinical trial of metadoxine in … Continue Reading
Premium
